E. Pearson

First name

E.

Middle name

R.

Last name

Pearson

Farmer, A. J., Rodgers, L. R., Lonergan, M., Shields, B., Weedon, M. N., Donnelly, L., et al. (2016). Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care. http://doi.org/10.2337/dc15-1194

View

Dennis, J. M., Henley, W. E., Weedon, M. N., Lonergan, M., Rodgers, L. R., Jones, A. G., et al. (2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. http://doi.org/10.2337/dc18-0344

View

Dennis, J. M., Shields, B. M., Hill, A. V., Knight, B. A., McDonald, T. J., Rodgers, L. R., et al. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. http://doi.org/10.2337/dc17-1827

View

Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., et al. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687

View

McGovern, A. P., Dennis, J. M., Shields, B. M., Hattersley, A. T., Pearson, E. R., & Jones, A. G. (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med. http://doi.org/10.1186/s12916-019-1307-8

View

McGovern, A. P., Hogg, M., Shields, B. M., Sattar, N. A., Holman, R. R., Pearson, E. R., et al. (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2020-001238

View